Perrigo Co. said today it will cut about 800 jobs and buy back some $2 billion of its shares as it streamlines operations and seeks to boost shareholder returns in the face of a hostile takeover bid by local generic drug giant Mylan.

"The actions we are announcing today to drive substantial profit growth make the gross inadequacy of Mylan's offer clearer than ever," chairman and CEO Joseph Papa said in a statement. "It is fundamentally irrational to believe that Mylan can run this business better or more profitably than our team."

The over-the-counter drug specialist said the job cuts represent about 6 percent of its global workforce. The Ireland-based company, which is operated out of Allegan, Mich., said it plans to repurchase $500 million worth of shares by the end of the year, with the remainder of the buybacks coming over the subsequent 2-1/2 years.

After being rejected by Perrigo's board, Mylan recently took its buyout offer of $75 in cash and 2.3 Mylan shares for each Perrigo share directly to Perrigo shareholders. The offer expires Nov. 13.

Advertise with us

Mylan reincorporated in the Netherlands this year but is run from executive offices in Cecil.

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.